Artemisinin Market Size, Share and Growth Outlook, 2026

Artemisinin Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Artemisinin Market size is forecast to increase from $763.23 Million in 2026 to $1444.39 Million in 2034 at a CAGR of 8.3% between 2026 and 2034.

The Artemisinin market report provides detailed analysis and outlook of Artemisinin segments including By Source (Natural Extraction, Biosynthetic / Semisynthetic Artemisinin), By Target Derivative Type (Artesunate, Artemether, Artemotil, Dihydroartemisinin), By Application (Antimalarial Tablets, Antimalarial Injections, Pediatric Antimalarial Formulations, Oncology & Inflammation Research Applications), By End-User (Finished Dosage Form, Research Institutes & Laboratory Facilities, Contract Manufacturing Organizations ), By Distribution Channel (B2B Supply Contracts, Institutional Procurement Channels) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Artemisinin Industry Overview

Focus on Malaria Control, Drug Resistance Management, and Treatment Accessibility

The artemisinin industry remains a critical component of the global malaria treatment landscape, with stakeholders concentrating on combating emerging drug resistance, strengthening manufacturing resilience, and improving access to life-saving artemisinin-based combination therapies (ACTs). As malaria-endemic countries continue to face evolving treatment challenges, industry participants, public health organizations, and governments are emphasizing innovation in diagnostics, therapeutics, and prevention strategies. Efforts are increasingly directed toward ensuring sustainable supply chains, expanding access to vulnerable patient populations, and supporting precision-based malaria control programs. These developments are shaping the future of artemisinin production and deployment while reinforcing its importance in global malaria eradication initiatives.

Advancements in Pediatric Malaria Treatment and Domestic Production Capacity

A major milestone in the industry was the World Health Organization’s prequalification of a new infant-specific artemether-lumefantrine formulation. This represents the first ACT specifically designed for newborns and young infants weighing between 2 kg and 5 kg, addressing a significant treatment gap affecting approximately 30 million babies born annually in malaria-endemic regions. The formulation supports public-sector procurement programs and is intended to reduce dosing errors and toxicity risks associated with the use of adult formulations in infants. Alongside therapeutic innovation, supply chain security has become a major priority. Manus Bio initiated the development of a domestic biomanufacturing facility in Augusta, Georgia, supported by a $47.4 million federal partnership with the U.S. Department of Health and Human Services under the Defense Production Act Title III program. The facility will integrate advanced biomanufacturing and flow chemistry technologies to establish domestic artemisinin production and reduce dependence on overseas agricultural supply chains.

Resistance Surveillance and Precision Malaria Intervention Programs

The growing spread of artemisinin partial resistance across several African countries, including Eritrea, Rwanda, Uganda, and Tanzania, has intensified global efforts to preserve treatment effectiveness. In response, health organizations are prioritizing resistance mitigation strategies that include the development of new combination partner drugs and the adoption of alternative rapid diagnostic tests targeting the pf-LDH protein. These diagnostic innovations are becoming increasingly important as traditional HRP2-based tests face reliability challenges due to parasite gene deletions. At the policy level, malaria-endemic nations are expanding nationally led precision intervention programs focused on targeted disease prevention and treatment. Seasonal Malaria Chemoprevention (SMC) initiatives now reach approximately 54 million children, while new-generation mosquito nets incorporating piperonyl butoxide (PBO) or dual active ingredients accounted for 84% of newly distributed nets during recent implementation campaigns. These integrated strategies are strengthening malaria control efforts while supporting the long-term effectiveness of artemisinin-based therapies.

Artemisinin Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Artemisinin market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- KPC Pharmaceuticals, Inc., Sanofi S.A., Guilin Pharmaceutical Co., Ltd., Kerui Group (Artemisinin Biotech), Chongqing Hengkang Pharmaceutical Co., Ltd., Guangxi Xiancaotang Pharmaceutical Co., Ltd., Alchem International Pvt. Ltd., Artemis International Inc., Natural Remedies Pvt. Ltd., Sanmark Corp.. The Artemisinin market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Artemisinin industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Artemisinin Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Artemisinin companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Artemisinin markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Artemisinin Market Competitive Benchmarking and Company Analysis

Leading companies in Artemisinin industry include- KPC Pharmaceuticals, Inc., Sanofi S.A., Guilin Pharmaceutical Co., Ltd., Kerui Group (Artemisinin Biotech), Chongqing Hengkang Pharmaceutical Co., Ltd., Guangxi Xiancaotang Pharmaceutical Co., Ltd., Alchem International Pvt. Ltd., Artemis International Inc., Natural Remedies Pvt. Ltd., Sanmark Corp.. The Artemisinin market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Artemisinin Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Artemisinin market remains one of the strongest-performing segments in the country.
The US Artemisinin Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Artemisinin market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Artemisinin industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Artemisinin markets

Canada's strong Artemisinin sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Artemisinin market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Artemisinin Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Artemisinin market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Artemisinin population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Artemisinin industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Artemisinin market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Artemisinin sales through 2034

France Artemisinin companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Artemisinin Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Artemisinin distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Artemisinin Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Artemisinin market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Artemisinin industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Artemisinin industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Artemisinin Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Artemisinin market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Artemisinin market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Artemisinin Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Artemisinin Market Segmentation

By Source
Natural Extraction
Biosynthetic / Semisynthetic Artemisinin
By Target Derivative Type
Artesunate
Artemether
Artemotil
Dihydroartemisinin
By Application
Antimalarial Tablets
Antimalarial Injections
Pediatric Antimalarial Formulations
Oncology & Inflammation Research Applications
By End-User
Finished Dosage Form
Research Institutes & Laboratory Facilities
Contract Manufacturing Organizations
By Distribution Channel
B2B Supply Contracts
Institutional Procurement Channels

Top Companies in Artemisinin Industry

KPC Pharmaceuticals, Inc.
Sanofi S.A.
Guilin Pharmaceutical Co., Ltd.
Kerui Group (Artemisinin Biotech)
Chongqing Hengkang Pharmaceutical Co., Ltd.
Guangxi Xiancaotang Pharmaceutical Co., Ltd.
Alchem International Pvt. Ltd.
Artemis International Inc.
Natural Remedies Pvt. Ltd.
Sanmark Corp.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025